Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents?
Abstract Background The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing with obesity, and it is believed that the ongoing low-grade inflammation in obesity and alterations in the enterohepatic axis contributing this process. This study aimed to determine the role of fecal calpro...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Pediatrics |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12887-024-05327-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544315092860928 |
|---|---|
| author | Büşra Tetik Dinçer Ayşe Merve Usta Alev Kural Nazlı Helvacı Ahmet Uçar Nafiye Urgancı |
| author_facet | Büşra Tetik Dinçer Ayşe Merve Usta Alev Kural Nazlı Helvacı Ahmet Uçar Nafiye Urgancı |
| author_sort | Büşra Tetik Dinçer |
| collection | DOAJ |
| description | Abstract Background The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing with obesity, and it is believed that the ongoing low-grade inflammation in obesity and alterations in the enterohepatic axis contributing this process. This study aimed to determine the role of fecal calprotectin (FC) as inflammatory biomarker in obesity and NAFLD. Methods Between November 2022-August 2023, 31 obese and 10 healthy adolescents aged between 10 and 18 years enrolled in this prospective controlled study. Body mass index higher than 2 standard deviation is considered as obesity. Obese adolescents were divided into two subgroups: obese adolescents (n = 11) and Obese + NAFLD group (n = 20). NAFLD diagnosis was made with biochemical analysis or ultrasonography. FC levels and laboratory parameters analyzed in study group, while only FC samples taken from control group. Anthropometric and laboratory parameters were compared between groups. This study was registered in ClinicalTrials.gov (NCT06229184). Results The median (IQR P25-75) FC levels in the obese + NAFLD, obese and the healthy controls were 136.23 (43.36-332.04), 61.77 (29.70-285.92) and 38.95 (27.59–50.52) µg/g feces, respectively (p = 0.018). Subgroup analyses revealed that the significant difference was between the obese + NAFLD group and the control group (p = 0.02), while no significant differences were observed between the control and obese groups, or between the obese and obese + NAFLD groups. FC positivity rates were 20% (n = 2) in the control group, 54.5% (n = 6) in the obese group, and 75% (n = 15) in the Obese + NAFLD group (p = 0.018). Conclusions FC is significantly higher in obese adolescents compared to healthy peers, but no significant difference was observed between obese and obese + NAFLD groups. Further studies needed on this subject. Trial registration This trial is registered in ClinicalTrials.gov (Trial registration number [ClinicalTrials.gov ID] NCT06229184). |
| format | Article |
| id | doaj-art-c9e7823ff0be45c2b339d48f26add689 |
| institution | Kabale University |
| issn | 1471-2431 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Pediatrics |
| spelling | doaj-art-c9e7823ff0be45c2b339d48f26add6892025-01-12T12:40:10ZengBMCBMC Pediatrics1471-24312024-12-012411710.1186/s12887-024-05327-4Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents?Büşra Tetik Dinçer0Ayşe Merve Usta1Alev Kural2Nazlı Helvacı3Ahmet Uçar4Nafiye Urgancı5Department of Pediatrics, Sisli Hamidiye Etfal Training and Research Hospital, University of Health SciencesDepartment of Pediatrics, Division of Pediatric Gastroenterology, Sisli Hamidiye Etfal Training and Research Hospital, University of Health SciencesDepartment of Biochemistry, Bakırkoy Sadi Konuk Training and Research Hospital, University of Health SciencesDepartment of Biochemistry, Bakırkoy Sadi Konuk Training and Research Hospital, University of Health SciencesDepartment of Pediatrics, Division of Pediatric Endocrinology, Sisli Hamidiye Etfal Training and Research Hospital, University of Health SciencesDepartment of Pediatrics, Division of Pediatric Gastroenterology, Sisli Hamidiye Etfal Training and Research Hospital, University of Health SciencesAbstract Background The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing with obesity, and it is believed that the ongoing low-grade inflammation in obesity and alterations in the enterohepatic axis contributing this process. This study aimed to determine the role of fecal calprotectin (FC) as inflammatory biomarker in obesity and NAFLD. Methods Between November 2022-August 2023, 31 obese and 10 healthy adolescents aged between 10 and 18 years enrolled in this prospective controlled study. Body mass index higher than 2 standard deviation is considered as obesity. Obese adolescents were divided into two subgroups: obese adolescents (n = 11) and Obese + NAFLD group (n = 20). NAFLD diagnosis was made with biochemical analysis or ultrasonography. FC levels and laboratory parameters analyzed in study group, while only FC samples taken from control group. Anthropometric and laboratory parameters were compared between groups. This study was registered in ClinicalTrials.gov (NCT06229184). Results The median (IQR P25-75) FC levels in the obese + NAFLD, obese and the healthy controls were 136.23 (43.36-332.04), 61.77 (29.70-285.92) and 38.95 (27.59–50.52) µg/g feces, respectively (p = 0.018). Subgroup analyses revealed that the significant difference was between the obese + NAFLD group and the control group (p = 0.02), while no significant differences were observed between the control and obese groups, or between the obese and obese + NAFLD groups. FC positivity rates were 20% (n = 2) in the control group, 54.5% (n = 6) in the obese group, and 75% (n = 15) in the Obese + NAFLD group (p = 0.018). Conclusions FC is significantly higher in obese adolescents compared to healthy peers, but no significant difference was observed between obese and obese + NAFLD groups. Further studies needed on this subject. Trial registration This trial is registered in ClinicalTrials.gov (Trial registration number [ClinicalTrials.gov ID] NCT06229184).https://doi.org/10.1186/s12887-024-05327-4AdolescentFecal calprotectinNon-alcoholic fatty liver diseaseObesity |
| spellingShingle | Büşra Tetik Dinçer Ayşe Merve Usta Alev Kural Nazlı Helvacı Ahmet Uçar Nafiye Urgancı Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents? BMC Pediatrics Adolescent Fecal calprotectin Non-alcoholic fatty liver disease Obesity |
| title | Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents? |
| title_full | Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents? |
| title_fullStr | Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents? |
| title_full_unstemmed | Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents? |
| title_short | Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents? |
| title_sort | can fecal calprotectin be used as a biomarker of non alcoholic fatty liver disease in obese adolescents |
| topic | Adolescent Fecal calprotectin Non-alcoholic fatty liver disease Obesity |
| url | https://doi.org/10.1186/s12887-024-05327-4 |
| work_keys_str_mv | AT busratetikdincer canfecalcalprotectinbeusedasabiomarkerofnonalcoholicfattyliverdiseaseinobeseadolescents AT aysemerveusta canfecalcalprotectinbeusedasabiomarkerofnonalcoholicfattyliverdiseaseinobeseadolescents AT alevkural canfecalcalprotectinbeusedasabiomarkerofnonalcoholicfattyliverdiseaseinobeseadolescents AT nazlıhelvacı canfecalcalprotectinbeusedasabiomarkerofnonalcoholicfattyliverdiseaseinobeseadolescents AT ahmetucar canfecalcalprotectinbeusedasabiomarkerofnonalcoholicfattyliverdiseaseinobeseadolescents AT nafiyeurgancı canfecalcalprotectinbeusedasabiomarkerofnonalcoholicfattyliverdiseaseinobeseadolescents |